Compare IMMP & ELWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | ELWT |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | Australia | United States |
| Employees | N/A | 34 |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 58.5M |
| IPO Year | 2012 | N/A |
| Metric | IMMP | ELWT |
|---|---|---|
| Price | $0.43 | $6.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 404.7K | 49.3K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $445.09 | $28.81 |
| Revenue Next Year | N/A | $70.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $4.11 |
| 52 Week High | $3.53 | $9.72 |
| Indicator | IMMP | ELWT |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 54.03 |
| Support Level | $0.42 | $6.61 |
| Resistance Level | $0.56 | $7.36 |
| Average True Range (ATR) | 0.03 | 0.70 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 72.99 | 54.13 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Elauwit Connection Inc is a provider of broadband Internet networks for the multifamily and student housing property sector. It designs, installs, operates, and maintains new fiber-optic and WiFi networks throughout each contracted property. Once installed, property owners begin selling Internet connectivity over Elauwit's network directly to their residents at monthly prices and terms of their choosing. Elauwit, in turn, provides all resident activation, onboarding, customer support, and network monitoring and maintenance services in exchange for a fixed monthly fee based on the number of units in the property times a monthly per-unit wholesale price. Its contracts with property owners generally have five to eight-year terms. Geographically, the company mainly operates in the U.S.